161 related articles for article (PubMed ID: 8692971)
1. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines.
Davis HL; McCluskie MJ; Gerin JL; Purcell RH
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7213-8. PubMed ID: 8692971
[TBL] [Abstract][Full Text] [Related]
2. DNA-based immunization against the envelope proteins of the hepatitis B virus.
Mancini M; Davis H; Tiollais P; Michel ML
J Biotechnol; 1996 Jan; 44(1-3):47-57. PubMed ID: 8717386
[TBL] [Abstract][Full Text] [Related]
3. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of hepatitis B virus (HBV) by human monoclonal antibody against HBV surface antigen (HBsAg) in chimpanzees.
Kim SH; Shin YW; Hong KW; Chang KH; Ryoo KH; Paik SH; Kim JM; Brotman B; Pfahler W; Prince AM
Antiviral Res; 2008 Sep; 79(3):188-91. PubMed ID: 18479762
[TBL] [Abstract][Full Text] [Related]
5. Successful postexposure vaccination against hepatitis B in chimpanzees.
Iwarson S; Wahl M; Ruttimann E; Snoy P; Seto B; Gerety RJ
J Med Virol; 1988 Aug; 25(4):433-9. PubMed ID: 3171558
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity in chimpanzees of experimental hepatitis B vaccines prepared from intact hepatitis B virus, purified polypeptides, or polypeptide micelles.
Tabor E; Howard CR; Skelly J; Snoy P; Goudeau A; Zuckerman AJ; Gerety RJ
J Med Virol; 1982; 10(1):65-74. PubMed ID: 7130967
[TBL] [Abstract][Full Text] [Related]
7. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus.
Ogata N; Cote PJ; Zanetti AR; Miller RH; Shapiro M; Gerin J; Purcell RH
Hepatology; 1999 Sep; 30(3):779-86. PubMed ID: 10462386
[TBL] [Abstract][Full Text] [Related]
8. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.
Channarong S; Mitrevej A; Sinchaipanid N; Usuwantim K; Kulkeaw K; Chaicumpa W
Asian Pac J Allergy Immunol; 2007 Dec; 25(4):233-42. PubMed ID: 18402297
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein.
Emini EA; Larson V; Eichberg J; Conard P; Garsky VM; Lee DR; Ellis RW; Miller WJ; Anderson CA; Gerety RJ
J Med Virol; 1989 May; 28(1):7-12. PubMed ID: 2723618
[TBL] [Abstract][Full Text] [Related]
10. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.
Michel ML; Davis HL; Schleef M; Mancini M; Tiollais P; Whalen RG
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5307-11. PubMed ID: 7777503
[TBL] [Abstract][Full Text] [Related]
11. Anamnestic response to hepatitis B vaccine in nonalcoholic liver cirrhosis patients with and without HBV-DNA.
Baruch Y; Enat R; Gershoni-Baruch R; Rimon N; Ben-Porath E
Am J Gastroenterol; 1992 May; 87(5):613-6. PubMed ID: 1534439
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of hepatitis B vaccine in chimpanzees given transfusions of highly infective blood.
Karasawa T; Shikata T; Abe K; Horiuchi R; Takahashi T; Yoshihara N; Mayumi M; Suzuki H; Oda T
J Infect Dis; 1983 Feb; 147(2):327-35. PubMed ID: 6827148
[TBL] [Abstract][Full Text] [Related]
13. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
Avdicova M; Crasta PD; Hardt K; Kovac M
Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750
[TBL] [Abstract][Full Text] [Related]
14. Antibodies recognizing human serum albumin are not elicited by immunization with preS2 sequences of the hepatitis B virus envelope protein.
Neurath AR; Strick N; Parker K; Kent SB
J Med Virol; 1988 Feb; 24(2):137-51. PubMed ID: 3351483
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.
Wheeler CM; Bautista OM; Tomassini JE; Nelson M; Sattler CA; Barr E;
Vaccine; 2008 Jan; 26(5):686-96. PubMed ID: 18164106
[TBL] [Abstract][Full Text] [Related]
16. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).
Fujisawa Y; Kuroda S; Van Eerd PM; Schellekens H; Kakinuma A
Vaccine; 1990 Jun; 8(3):192-8. PubMed ID: 2363298
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of serum markers of infection and naturally acquired immunity to hepatitis B virus in transfused children treated at a children's hospital in Salvador, Bahia: A cross-sectional study.
Martinez VO; D'Arede SO; de Almeida ES; Lima FWM
Pediatr Hematol Oncol; 2018; 35(7-8):422-426. PubMed ID: 30588876
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients.
Kara IH; Yilmaz ME; Suner A; Kadiroglu AK; Isikoglu B
Vaccine; 2004 Sep; 22(29-30):3963-7. PubMed ID: 15364445
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing.
Neurath AR; Kent SB; Parker K; Prince AM; Strick N; Brotman B; Sproul P
Vaccine; 1986 Mar; 4(1):35-7. PubMed ID: 2421497
[TBL] [Abstract][Full Text] [Related]
20. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
